Simonsen Anders Lykkemark, Danborg Pia Brandt, Gøtzsche Peter Christian
Int J Risk Saf Med. 2016 Mar 16;28(1):1-12. doi: 10.3233/JRS-160668.
Sexual dysfunction is a common adverse effect of selective serotonin reuptake inhibitors (SSRIs) and there is a concern that the sexual harms might persist after discontinuation of therapy.
To assess whether the use of SSRIs in animals can lead to persistent sexual dysfunction.
Systematic review of animal studies measuring sexual behaviour after end of treatment with SSRIs or serotonin norepinephrine reuptake inhibitors.
We searched PubMed and EMBASE.
We included 14 studies. The general quality of the studies was poor. Only four studies reported use of randomisation and none mentioned allocation concealment. All studies used placebo and were therefore blinded. For rats exposed to SSRIs compared with those exposed to placebo, we found a higher risk of no mounting behaviour (RR = 0.73; 95% CI = 0.62-0.86), no intromission behaviour (RR = 0.74; 95% CI = 0.60-0.92) and no ejaculation behaviour (RR = 0.49, 95% CI = 0.24-1.00).
Our results showed substantial and lasting effects on sexual behaviour in rats after exposure to an SSRI early in life on important sexual outcomes.
性功能障碍是选择性5-羟色胺再摄取抑制剂（SSRIs）常见的不良反应，人们担心停药后性方面的损害可能持续存在。
评估在动物中使用SSRIs是否会导致持续性性功能障碍。
对测量SSRIs或5-羟色胺去甲肾上腺素再摄取抑制剂治疗结束后性行为的动物研究进行系统评价。
检索了PubMed和EMBASE。
纳入14项研究。这些研究的总体质量较差。只有4项研究报告采用了随机分组，无一提到分配隐藏。所有研究均使用了安慰剂，因此采用了盲法。与暴露于安慰剂的大鼠相比，暴露于SSRIs的大鼠出现无爬跨行为（RR = 0.73；95%CI = 0.62 - 0.86）、无插入行为（RR = 0.74；95%CI = 0.60 - 0.92）和无射精行为（RR = 0.49，95%CI = 0.24 - 1.00）的风险更高。
我们的结果表明，早年暴露于SSRI对大鼠性行为的重要性方面结局有显著且持久的影响。
